Primary HPV screening for cervical cancer prevention: Results from European trials

Nature Reviews Clinical Oncology

Volumn 6, Issue 12, 2009, Pages 699-706

  Lynge, Elsebeth ^a   Rebolj, Matejka ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GRADING; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; EUROPE; HUMAN; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS; FEMALE; GENETICS; MASS SCREENING; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; VIROLOGY;

VIRUS DNA;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS AS TOPIC; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 75649091547     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.167     Document Type: Review

References (25)

1. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 90: Human Papillomaviruses (International Agency for Research on Cancer, Lyon, 2007).
2. IARC. IARC Handbooks of Cancer Prevention, Volume 10: Cervix cancer screening (International Agency for Research on Cancer, Lyon, 2005).
3. Koliopoulos, G. et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and metaanalysis of non-randomized studies. Gynecol. Oncol. 104, 232-246 (2007 (Pubitemid 46054137)
4. Cuzick, J. et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 (Suppl. 10), K29-K41 (2008).
5. Elfgren, K. et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am. J. Obstet. Gynecol. 193, 650-657 (2005 (Pubitemid 41261457)
6. Naucler, P. et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357, 1589-1597 (2007 (Pubitemid 47598401)
7. Naucler, P. et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl Cancer Inst. 101, 88-99 (2009).
8. Bulkmans, N. W. et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer 110, 94-101 (2004).
9. Bulkmans, N. W. et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370, 1764-1772 (2007).
10. Ronco, G. et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 7, 547-555 (2006 (Pubitemid 43923665)
11. Ronco, G. et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl Cancer Inst. 98, 765-774 (2006 (Pubitemid 43923665)
12. Ronco, G. et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl Cancer Inst. 100, 492-501 (2008).
13. Kitchener, H. C. et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br. J. Cancer 95, 56-61 (2006).
14. Kotaniemi-Talonen, L. et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br. J. Cancer 93, 862-867 (2005 (Pubitemid 41487010)
15. Kotaniemi-Talonen, L. et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur. J. Cancer 44, 565-571 (2008).
16. Sankaranarayanan, R. et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360, 1385-1394 (2009).
17. Mayrand, M. H. et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int. J. Cancer 119, 615-623 (2006).
18. Mayrand, M. H. et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357, 1579-1588 (2007).
19. Davies, P. et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int. J. Cancer 118, 791-796 (2006 (Pubitemid 43157653)
20. Clayton, D. & Hills, M. Statistical Models in Epidemiology (Oxford University Press, Oxford, 1993).
21. Chaudhary, M. A. & Stearns, S. C. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat. Med. 15, 1447-1458 (1996).
22. Rebolj, M. et al. Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: comparison of costs and side effects of three alternative strategies. Int. J. Cancer 121, 1529-1535 (2007 (Pubitemid 47328712)
23. Svendsen, A. L. et al. Breast cancer incidence after the introduction of mammography screening: what should be expected? Cancer 106, 1883-1890 (2006).
24. National Cancer Institute. Cervical cancer screening: HPV testing [online], http://www.cancer.gov/cancertopics/pdq/screening/cervical/ healthprofessional/page9 (2009).
25. Rappaport, K. M. et al. Adoption of liquid-based cervical cancer screening tests by family physicians and gynecologists. Health Serv. Res. 39, 927-947 (2004).